Persistent hypercalcemia after parathyroidectomy in an adolescent and effect of treatment with cinacalcet HCl

Clinical Chemistry

Volumn 52, Issue 12, 2006, Pages 2286-2293

  Henrich, Lorin M ^a   Rogol, Alan D ^a   D'Amour, Pierre ^b   Levine, Michael A ^c   Hanks, John E ^a   Bruns, David E ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF MONTREAL   (Canada)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CINACALCET;

ADOLESCENT; ARTICLE; CALCIUM BLOOD LEVEL; CASE REPORT; CLINICAL FEATURE; HORMONE DETERMINATION; HUMAN; HYPERCALCEMIA; LABORATORY DIAGNOSIS; MALE; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROIDECTOMY; PHARMACODYNAMICS; PHOSPHATE BLOOD LEVEL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; CALCIUM; DIAGNOSIS, DIFFERENTIAL; HUMANS; HYPERCALCEMIA; HYPERPARATHYROIDISM, PRIMARY; MALE; NAPHTHALENES; PARATHYROID HORMONE; PARATHYROIDECTOMY; PHOSPHORUS;

EID: 33845516724     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2006.070219     Document Type: Article

References (51)

1. Kollars J, Zarroug AE, van Heerden J, Lteif A, Stavlo P, Suarez L, et al. Primary hyperparathyroidism in pediatric patients. Pediatrics 2005;115:974-80.
2. Allo M, Thompson NW, Harness JK, Nishiyama RH. Primary hyperparathyroidism in children, adolescents, and young adults. World J Surg 1982;6:771-6.
3. Bjernulf A, Hall K, Sjogren L, Werner I. Primary hyperparathyroidism in children: Brief review of the literature and a case report. Acta Paediatr Scand 1970;59249-58.
4. Bringhurst FR, Demay MB, Kronenber HM. Hormones and Disorders of Mineral Metabolism. In: Larsen PR, Kronenberg HM, Melmed S, Polonsky KS, eds. Williams Textbook of Endocrinology. Tenth ed. Philadelphia: Saunders;2003:1303-71.
5. Bilezikian JP, Potts JT Jr, Fuleihan G, Kleerekoper M, Neer R, Peacock M, et al. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Clin Endocrinol Metab 2002;87:5353-61.
6. Barman Balfour JA, Scott LJ. Cinacalcet hydrochloride. Drugs 2005;65:271-81.
7. Joy MS, Kshirsagar AV, Franceschini N. Calcimimetics and the treatment of primary and secondary hyperparathyroidism. Ann Pharmacother 2004;38:1871-80.
8. Brown EM, Gamba G, Riccardi D, Lombardi M, Butters R, Kifor O, et al. Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature 1993;366:575-80.
9. Brown EM, Pollak M, Riccardi D, Hebert SC. Cloning and characterization of an extracellular Ca(2+)-sensing receptor from parathyroid and kidney: new insights into the physiology and pathophysiology of calcium metabolism. Nephrol Dial Transplant 1994; 9:1703-6.
10. Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA, Shoback D. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2005;90:135-41.
11. Shoback DM, Bilezikian JP, Turner SA, McCary LC, Guo MD, Peacock M. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab 2003;88:5644-9.
12. Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 2005;16:800-7.
13. Fisher DA, ed. Pediatric Endocrinology-Tests and Methods, Specimen Requirements, Test Selection and Interpretation. 1st ed. San Juan Capistrano: Quest Diagnostics Incorporated; 2000.
14. Younes NA, Shafagoj Y, Khatib F, Ababneh M. Laboratory screening for hyperparathyroidism. Clin Chim Acta 2005;353:1-12.
15. Marx SJ, Attie MF, Stock JL, Spiegel AM, Levine MA. Maximal urine-concentrating ability: familial hypocalciuric hypercalcemia versus typical primary hyperparathyroidism. J Clin Endocrinol Metab 1981;52:736-40.
16. Eronen M, Peippo M, Hiippala A, Raatikka M, Arvio M, Johansson R, et al. Cardiovascular manifestations in 75 patients with Williams syndrome. J Med Genet 2002;39:554-8.
17. Weiss RL, ed. ARUP's Guide to Pediatric Clinical Laboratory Testing. 2nd ed. Salt Lake City: ARUP Laboratories, Inc.; 2000.
18. Silverman R, Yalow RS. Heterogeneity of parathyroid hormone: clinical and physiologic implications. J Clin Invest 1973;52:1958-71.
19. AACE/AAES Task Force on Primary Hyperparathyroidism. The American Association of Clinical Endocrinologists and the American Association of Endocrine Surgeons position statement on the diagnosis and management of primary hyperparathyroidism. Endocr Pract 2005;11:49-54.
20. Bieglmayer C, Prager G, Niederle B. Kinetic analyses of parathyroid hormone clearance as measured by three rapid immunoassays during parathyroidectomy. Clin Chem 2002;48:1731-8.
21. Hendy GN, D'Souza-Li L, Yang B, Canaff L, Cole DE. Mutations of the calcium-sensing receptor (CASR) in familial hypocalciuric hypercalcemia, neonatal severe hyperparathyroidism, and autosomal dominant hypocalcemia. Hum Mutat 2000;16:281-96.
22. Lepage R, Whittom S, Bertrand S, Bahsali G, D'Amour P. Superiority of dynamic over static reference intervals for intact, mid-molecule, and C-terminal parathyrin in evaluating calcemic disorders. Clin Chem 1992;38:2129-35.
23. Lepage R, D'Amour P, Boucher A, Hamel L, Demontigny C, Labelle F. Clinical performance of a parathyrin immunoassay with dynamically determined reference values. Clin Chem 1988;34:2439-43.
24. D'Amour P, Rakel A, Brassard JH, Rousseau L, Albert C, Cantor T. Acute regulation of circulating parathyroid hormone (PTH) molecular forms by calcium: utility of PTH fragments/PTH(1-84) ratios derived from three generations of PTH assays. J Clin Endocrinol Metab 2006;91:283-9.
25. Davies M, Fraser WD, Hosking DJ. The management of primary hyperparathyroidism. Clin Endocrinol (Oxf) 2002;57:145-55.
26. Bai M, Quinn S, Trivedi S, Kifor O, Pearce SH, Pollak MR, et al. Expression and characterization of inactivating and activating mutations in the human Ca2+o-sensing receptor. J Biol Chem 1996;271:19537-45.
27. Levine M, Zapalowski C, Kappy M. Disorders of calcium, phosphate, parathyroid hormone and vitamin D. In: Kappy M, Allen D, Geffner M, eds. Principles and Practice of Pediatric Endocrinology. Springfield: CC Thomas;2005:695-813.
28. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001;86:5658-71.
29. Goodman WG. Calcimimetic agents and secondary hyperparathyroidism: rationale for use and results from clinical trials. Pediatr Nephrol 2003;18:1206-10.
30. D'Amour P, Palardy J, Bahsali G, Mallette LE, DeLean A, Lepage R. The modulation of circulating parathyroid hormone immunoheterogeneity in man by ionized calcium concentration. J Clin Endocrinol Metab 1992;74:525-32.
31. Mayer GP, Keaton JA, Hurst JG, Habener JF. Effects of plasma calcium concentration on the relative proportion of hormone and carboxyl fragments in parathyroid venous blood. Endocrinology 1979;104:1778-84.
32. Brossard JH, Lepage R, Cardinal H, Roy L, Rousseau L, Dorais C, et al. Influence of glomerular filtration rate on non-(1-84) parathyroid hormone (PTH) detected by intact PTH assays. Clin Chem 2000;46:697-703.
33. Brossard JH, Cloutier M, Roy L, Lepage R, Gascon-Barre M, D'Amour P. Accumulation of a non-(1-84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: importance in the interpretation of PTH values. J Clin Endocrinol Metab 1996;81:3923-9.
34. Goodman WG. New assays for parathyroid hormone (PTH) and the relevance of PTH fragments in renal failure. Kidney Int Suppl 2003;87:S120-4.
35. Gao P, D'Amour P. Evolution of the parathyroid hormone (PTH) assay-importance of circulating PTH immunoheterogeneity and of its regulation. Clin Lab 2005;51:21-9.
36. Lepage R, Roy L, Brassard JH, Rousseau L, Dorais C, Lazure C, et al. A non-(1-84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples. Clin Chem 1998;44:805-9.
37. Nussbaum SR, Zahradnik RJ, Lavigne JR, Brennan GL, Nozawa-Ung K, Kim LY, et al. Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 1987;33:1364-7.
38. Quarles LD, Lobaugh B, Murphy G. Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 1992; 75:145-50.
39. John MR, Goodman WG, Gao P, Cantor TL, Salusky IB, Juppner H. A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure. J Clin Endocrinol Metab 1999;84:4287-90.
40. Gao P, Scheibel S, D'Amour P, John MR, Rao SD, Schmidt-Gayk H, et al. Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res 2001;16:605-14.
41. Abdelrahman A, Wan B, Grossi A, Makela S, Ellis G. IMMULITE chemiluminescent immunoassay for PTH in pediatric samples compared to Nichols institute immunoradiometric assay. Clin Biochem 1997;30:374.
42. Nakanishi S, Kazama JJ, Shigematsu T, Iwasaki Y, Cantor TL, Kurosawa T, et al. Comparison of intact PTH assay and whole PTH assay in long-term dialysis patients. Am J Kidney Dis 2001;38(4 Suppl 1):S172-4.
43. Sheth RD, Goldstein SL. Comparison of 1-84 and intact parathyroid hormone assay in pediatric dialysis patients. Pediatr Nephrol 2005;20:977-81.
44. Reichel H, Esser A, Roth HJ, Schmidt-Gayk H. Influence of PTH assay methodology on differential diagnosis of renal bone disease. Nephrol Dial Transplant 2003;18:759-68.
45. Slatopolsky E, Finch J, Clay P, Martin D, Sicard G, Singer G, et al. A novel mechanism for skeletal resistance in uremia. Kidney Int 2000;58:753-61.
46. Savoca R, Bock A, Kraenzlin ME, Schmid HR, Huber AR. An automated 'bio-intact' PTH assay: a step towards standardisation and improved correlation with parathyroid function in renal disease. Clin Chim Acta 2004;343:167-71.
47. Martin KJ, Juppner H, Sherrard DJ, Goodman WG, Kaplan MR, Nassar G, et al. First- and second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HCl. Kidney Int 2005;68:1236-43.
48. Armitage EK. Parathyrin (parathyroid hormone): metabolism and methods for assay. Clin Chem 1986;32:418-24.
49. D'amour P, Brossard JH. Carboxyl-terminal parathyroid hormone fragments: role in parathyroid hormone physiopathology. Curr Opin Nephrol Hypertens 2005;14:330-6.
50. D'Amour P, Brossard JH, Rousseau L, Roy L, Gao P, Cantor T. Amino-terminal form of parathyroid hormone (PTH) with immunologic similarities to hPTH(1-84) is overproduced in primary and secondary hyperparathyroidism. Clin Chem 2003;49:2037-44.
51. Roos BA, Lindall AW, Aron DC, Orf JW, Yoon M, Huber MB, et al. Detection and characterization of small midregion parathyroid hormone fragment (s) in normal and hyperparathyroid glands and sera by immunoextraction and region-specific radioimmunoassays. J Clin Endocrinol Metab 1981;53:709-21.